Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TPST-1120 by Tempest Therapeutics for Renal Cell Carcinoma: Likelihood of Approval
TPST-1120 is under clinical development by Tempest Therapeutics and currently in Phase I for Renal Cell Carcinoma. According to GlobalData,...
TPST-1120 by Tempest Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval
TPST-1120 is under clinical development by Tempest Therapeutics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Tempest Therapeutics's TPST-1120?
TPST-1120 is a small molecule commercialized by Tempest Therapeutics, with a leading Phase II program in Metastatic Hepatocellular Carcinoma (HCC)....